Effects of Atypical Antipsychotics on Brain Function in Children and Teens With Conduct Disorders
NCT ID: NCT01867398
Last Updated: 2019-12-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
12 participants
OBSERVATIONAL
2013-04-29
2015-05-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
\- Some children and teenagers have conditions known as conduct disorders. They often have long-term chronic behavior problems, such as defiant behavior or violence. Conduct disorders are often treated with antipsychotic medication. Researchers want to study two types of newer antipsychotics (aripiprizole and risperidone) for children and adolescents with conduct disorders. They will look at how these drugs affect brain activity. To do so, they will give brain activity tests using magnetic resonance imaging (MRI). The tests will compare the results from healthy volunteer children and teens to those of others with behavior problems.
Objectives:
\- To see how atypical antipsychotics affect brain activity of children and teenagers with conduct disorders.
Eligibility:
* Children and teenagers between 10 and 18 years of age who have a conduct disorder and are taking aripiprizole.
* Children and teenagers between 10 and 18 years of age who have a conduct disorder and are taking risperidone.
* Children and teenagers between 10 and 18 years of age who have a conduct disorder and are not taking an atypical antipsychotic.
* Healthy volunteers between 10 and 18 years of age.
Design:
* Participants will be screened with a physical exam and medical history. Parents/guardians will be asked questions about their child s feelings, experiences, and behavior. Participants will also answer questions about their feelings and moods.
* This study will involve two visits. Each visit will involve MRI scanning.
* At the first visit, participants will have memory and thinking tests. The tests will involve making decisions or playing games. Some of these tests will use MRI scanning to look at brain activity.
* The second visit will be 3 to 5 months after the first visit. The tests from the first visit will be repeated.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Population: Youth with CD receiving aripiprazole at admission to Boys Town Omaha, youth with CD receiving risperidone at admission to Boys Town Omaha, youth with CD not receiving antipsychotics at admission to Boys Town Omaha, typically developing youth.
Design: The study will involve a 4 (Group: CD receiving aripiprazole at admission, CD receiving risperidone at admission, CD not receiving antipsychotics at admission, typically developing youth) x 2 (Time: At admission vs. four months subsequent to admission \[when treatment for the antipsychotic groups will have been tapered off\]) design. Principle dependent measures will relate to BOLD response indices of the pathophysiology of CD.
Outcome Measures: Principle dependent measures will relate to BOLD response indices of the pathophysiology of CD. In addition, assessments of symptom severity will be collected, as will measurements of cognitive function.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. 10-18 years of age.
2. A current diagnosis of CD.
3. Currently taking aripiprazole, risperidone or unmedicated with antipsychotics.
Typically developing (TD) youth
1. 10-18 years of age.
2. No current psychiatric diagnosis.
Exclusion Criteria
2. Pregnancy.
3. Ongoing medical illness requiring the following medications:
* Beta blockers
* Steroids
* Receipt of any antipsychotic medication other than aripiprazole or risperidone.
* Receipt of risperidone for the CD group medicated with aripiprazole.
* Receipt of aripiprazole for the CD group medicated with risperidone.
* Receipt of antipsychotics for the un-medicated CD group.
* Explicit exclusions include active psychosis, Pervasive Developmental
* Neurologic disorder (including seizures).
* Any ferromagnetic metallic objects in the body. Metal plates, certain types of dental braces, cardiac pacemakers, etc., that are sensitive to electromagnetic fields contraindicate MRI scans.
* Claustrophobia
10 Years
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boys Town Research Hospital
UNKNOWN
National Institute of Mental Health (NIMH)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James J Blair, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute of Mental Health (NIMH)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Boys Town Research Hospital
Omaha, Nebraska, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62 Suppl 7:22-31.
Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL; Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002 Aug;159(8):1337-46. doi: 10.1176/appi.ajp.159.8.1337.
Bortolozzi A, Diaz-Mataix L, Toth M, Celada P, Artigas F. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl). 2007 Apr;191(3):745-58. doi: 10.1007/s00213-007-0698-y. Epub 2007 Jan 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13-M-N125
Identifier Type: -
Identifier Source: secondary_id
999913125
Identifier Type: -
Identifier Source: org_study_id